Abstract: The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs.
Type:
Application
Filed:
April 1, 2005
Publication date:
October 16, 2008
Applicant:
The Trustees of the University of Pennsylvania Center for Technology Transfer
Abstract: The present invention is directed to a compound of Formula I wherein R1, R2, R3, R4, R5, R6, W, X, Y, and Z are defined herein. The compounds of the present invention are useful as anticancer agents. Specifically, the compounds are useful for treating or preventing cancer and tumor growth. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to methods of using a compound according to the above formula.
Type:
Application
Filed:
March 19, 2004
Publication date:
June 28, 2007
Applicant:
The Trustees of the University of Pennsylvania Center for Technology Transfer
Abstract: This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.
Type:
Grant
Filed:
May 4, 2001
Date of Patent:
March 4, 2003
Assignee:
Trustees of the University of Pennsylvania, The Center for
Technology Transfer
Inventors:
Mortimer M. Civan, Richard A. Stone, Claire H. Mitchell, Kenneth A. Jacobson